REMDESIVIR News & Analysis

Three new vaccines for coronavirus look poised for emergency use authorisation in the US this autumn. What does that mean for investors?

Diagnostic testing, treatment, and a coronavirus vaccine could allow near-normal distancing and nonessential business recovery by mid-2021.

Diagnostics, treatment, and vaccine progress could allow near-normal distancing and nonessential business recovery by mid-2021, Morningstar says.

We take a closer look at the potential impact of remdesivir's nearly certain approval on our valuation model for Gilead.

The US is slowing the coronavirus spread as drug makers race toward a vaccine; while the longer-term economic effect will be modest, say Morningstar...